# Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

> **NCT00925301** · PHASE3 · COMPLETED · sponsor: **Amicus Therapeutics** · enrollment: 67 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** migalastat hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00925301
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-23
- **Primary completion:** 2012-06-12
- **Final completion:** 2014-01-29
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2018-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925301, "Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00925301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*